- |||||||||| Estreva oral (estradiol oral) / EMD Serono
Trial termination: Binge Eating & Birth Control (clinicaltrials.gov) - Jul 26, 2022
P2, N=8, Terminated,
Ozone had a positive effect on the treatment of Asherman syndrome and has a significant impact on achieving pregnancy. Active, not recruiting --> Terminated; Halted prematurely due to COVID-19-related enrollment challenges.
- |||||||||| Estreva oral (estradiol oral) / EMD Serono
Enrollment closed, Enrollment change: Binge Eating & Birth Control (clinicaltrials.gov) - May 6, 2022
P2, N=8, Active, not recruiting,
Active, not recruiting --> Terminated; Halted prematurely due to COVID-19-related enrollment challenges. Recruiting --> Active, not recruiting | N=15 --> 8
- |||||||||| Estreva oral (estradiol oral) / EMD Serono
Trial completion date, Trial primary completion date: Binge Eating & Birth Control (clinicaltrials.gov) - Feb 12, 2021
P2, N=15, Recruiting,
Recruiting --> Active, not recruiting | N=15 --> 8 Trial completion date: Jul 2021 --> Jul 2022 | Trial primary completion date: Jul 2021 --> Jul 2022
- |||||||||| Estreva oral (estradiol oral) / EMD Serono
Enrollment open, Trial initiation date: Binge Eating & Birth Control (clinicaltrials.gov) - Sep 23, 2020
P2, N=15, Recruiting,
Trial completion date: Jul 2021 --> Jul 2022 | Trial primary completion date: Jul 2021 --> Jul 2022 Not yet recruiting --> Recruiting | Initiation date: Apr 2020 --> Sep 2020
- |||||||||| Estreva oral (estradiol oral) / EMD Serono
New P2 trial: Binge Eating & Birth Control (clinicaltrials.gov) - Feb 19, 2020
P2, N=15, Not yet recruiting,
- |||||||||| Climara (estradiol) / Bausch Health, Bayer, Estreva oral (estradiol oral) / EMD Serono, Estraderm (estradiol) / Novartis
Trial completion, Phase classification, Enrollment change: Aging and Estrogen on Cortical Function (clinicaltrials.gov) - Aug 22, 2018
P1/2, N=38, Completed,
Oral contraception may be an effective method to induce ovulation for some patients with premature ovarian insufficiency. Active, not recruiting --> Completed | Phase classification: P4 --> P1/2 | N=60 --> 38
- |||||||||| Climara (estradiol) / Bausch Health, Bayer, Estreva oral (estradiol oral) / EMD Serono, Estraderm (estradiol) / Novartis
Enrollment closed, Phase classification, Trial primary completion date: Aging and Estrogen on Cortical Function (clinicaltrials.gov) - Mar 21, 2017
P4, N=60, Active, not recruiting,
Active, not recruiting --> Completed | Phase classification: P4 --> P1/2 | N=60 --> 38 Recruiting --> Active, not recruiting | Phase classification: PN/A --> P4 | Trial primary completion date: Sep 2015 --> Oct 2018
- |||||||||| Vivelle (estradiol transdermal system) / Sanofi, Hisamitsu, Novartis, Estreva oral (estradiol oral) / EMD Serono, Estrace (estradiol) / AbbVie
Trial completion: Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism (clinicaltrials.gov) - Dec 18, 2013
P4, N=41, Completed,
Recruiting --> Active, not recruiting | Phase classification: PN/A --> P4 | Trial primary completion date: Sep 2015 --> Oct 2018 Active, not recruiting --> Completed
|
